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total cost, quality-adjusted life years (QALYs), cumulative incidence of cirrhosis, 
decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related 
deaths (LRD). We also projected the number of new HCV infections in society due to 
HCV-infected people released from prisons. Results: The total costs under no and 
5YR screening were $6.9 million and $8.3 million per 10,000 people, respectively for 
30-year simulation. The corresponding QALYs were 190,428 and 190,462, respectively. 
The incremental cost-effectiveness ratio of 5YR screening was $43,000 per QALY. In 
comparison with no screening, 5YR screening can avoid 136,000 new HCV infections 
in the next 30 years, where 71% of these infections can be attributed to infected per-
sons released from prisons back in the society. The 5-year screening can also reduce 
the cumulative incidence of DC, HCC, LT and LRD by 14-17%. ConClusions: HCV 
screening followed by treatment in prisons is cost-effective at $50,000 willingness-
to-pay. Resources spent in prisons can substantially reduce the burden of HCV in 
both prisons and the society at large.
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objeCtives: The optimal management of patients with suspected biliary obstruc-
tion remains unclear, and includes the possible performance of magnetic resonance 
cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancrea-
tography (ERCP). We completed a medical effectiveness randomized trial comparing 
an ERCP-first to a MRCP-first approach in patients with suspected bile duct obstruc-
tion. Methods: The management strategies are based on a medical effectiveness 
trial of 257 patients over a 10-month follow-up period. Direct and indirect costs were 
included, adopting a societal perspective. The cost values are expressed in 2012 
Canadian dollars. Results: Direct costs attributable to visits were CAN$5350 in the 
ERCP and CAN$5750 in the MRCP group. The procedures costs were CAN$233,852 
and CAN$267,952 for the ERCP and MRCP groups, respectively. Second procedures 
were incurred twice more in the MRCP than in the ERCP group. Direct costs of com-
plications amounted to CAN$207,708 (ERCP group) and CAN$252,347 (MRCP group). 
Total direct costs added up to CAN$446,910 for the 126 patients in the ERCP-first 
strategy and CAN$525,689 for the 131 MRCP-first patients. With regards to indirect 
costs, MRCP group patients spent more days in scheduled GI visits (8 days) and 
hospitalizations (49 days), but less days in procedures (18 days) and in time away 
from activity of daily living (44 days). Overall total indirect costs were quite similar 
(ERCP-first CAN$92,219 versus MRCP-first CAN$90,912). ConClusions: This cost 
analysis suggests only a small difference in total costs, favoring the ERCP-first group, 
and is principally attributable to procedures and hospitalizations with little impact 
from indirect cost measurements.
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objeCtives: A decision-analytic Markov model was developed to predict the 
health outcomes of using sofosbuvir (SOF) -based regimen compared with cur-
rent treatment options for patients who are co-infected with hepatitis C (HCV) 
and HIV. Methods: The analysis modeled a cohort of treatment-naïve genotype 1 
patients co-infected with HIV and HCV with a mean age of 54 years and 25% with 
cirrhosis. The model was evaluated from a US third-party payer perspective for a 
lifetime time horizon. SOF+pegylated interferon + ribavirin (PR) for 12 weeks was 
compared with telaprevir (TVR)+PR for 48 weeks, and boceprevir (BOC)+PR for 48 
weeks. Sustained virologic response (SVR) rates were derived from clinical trials 
conducted in the HCV/HIV co-infected patient population. Transition probability, 
utility, and cost estimates were based on a literature review, public sources, and 
consensus by a panel of 4 hepatologists. Results: In the HCV/HIV co-infected 
cohort, the SOF-based regimen was associated with the lowest incidence of liver dis-
ease complications including hepatocellular carcinoma, decompensated cirrhosis, 
need for liver transplantation, and HCV-related death (reduction of 52% compared 
to TVR+PR and 65% compared to BOC+PR). In addition, patients receiving SOF+PR 
experienced more quality-adjusted life-years (QALYs), compared to those treated 
with other options (ranged from 0.63 to 1.10 QALYs). In terms of incremental qual-
ity adjusted life years gained, SOF+PR dominated over TVR+PR and BOC+PR. The 
sensitivity analysis indicated that the results were robust to changes in model 
inputs and assumptions, such as SVR rates, adverse event incidence, costs for treat-
ment monitoring and management of adverse events, and transition probability 
estimates. ConClusions: The SOF-based regimen of shorter duration, improved 
tolerability profile and high SVR rates was projected to yield the most favorable 
health and economic outcomes in the genotype 1 HIV and HCV co-infected popula-
tion compared to current treatment regimens using telaprevir or boceprevir.
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objeCtives: In recent years, there has been a rapid growth in the development of 
novel biological treatments. Numerous economic evaluations have been performed 
to evaluate these treatments in inflammatory bowel diseases (IBD). The objective 
of this project was to explore the existing evidences regarding the cost-effective-
ness of treatments in IBD. Methods: A systematic review of the literature was 
50% of Hepatitis C patients in Turkey are female and the mean age of patients is 50. 
Approximately 60% of patients are treatment naïve. Approximately 900 liver trans-
plants are performed in Turkey per year and the success rate is around 85%. From 
the payer’s perspective, the average annual cost (excluding hepatitis C drug costs) 
of a chronic hepatitis C, compensated cirrhosis, decompensated cirrhosis, hepato-
carcinoma and liver transplant patient is USD 446.83, USD 577.56, USD 1984.39, USD 
2474.15, USD 42,469.27 respectively. ConClusions: Early diagnosis and treatment 
is crucial not only from the clinical perspective, but also from the cost perspective 
as a more severe disease costs significantly more.
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objeCtives: New all oral HCV therapies are recognized as having higher cure rates 
than current standard of care (SOC) treatments. However, the cost-benefit of providing 
new all oral therapy versus SOC treatment is currently unknown. We undertook a 
study to examine the financial impact of anticipated all oral therapy for genotype 
1 disease and approved all oral therapy for genotypes 2 and 3 disease versus SOC 
treatments. Methods: We calculated pharmacy costs of approved drugs using 
wholesale acquisition costs, assuming a full course of therapy for genotypes 1, 2, 
and 3 diseases, respectively. Anticipated all oral therapy for genotype 1 was esti-
mated at 1.5 times the cost of all oral therapy for genotype 2. Costs for medical 
treatment over 14 years were based on published data for four therapeutic end-
points: cured, not cured and no cirrhosis, not cured with cirrhosis, not cured with 
cirrhosis and end stage liver disease. The study also accounted for the frequency 
of genotypes 1, 2, and 3 HCV disease within the U.S. population for pooled analysis 
across genotypes. Results: Genotype 1 all oral therapy is anticipated to provide 
overall cost savings of 13% compared to SOC. However, overall costs among approved 
genotypes 2 and 3 all oral therapy were 9% and 44% higher compared to SOC even 
with cure rates 20% and 18% higher. After accounting for genotype frequency 
within the general U.S. population, pooled analysis across genotypes showed a net 
cost savings of $1,248 per utilizing member per year for all oral treatment versus 
SOC. ConClusions: If our predicted cost of new genotype 1 therapy is accurate, 
cost savings will only be observed among the anticipated new all oral therapy for 
genotype 1 disease. However, these savings will provide a net cost savings across 
genotypes for all oral therapy compared to SOC treatment.
PGI12
Cost-EffECtIvEnEss of adalImumab for thE trEatmEnt of modEratEly 
to sEvErEly aCtIvE ulCEratIvE ColItIs In Canada
Ghosh S.1, Desjardins O.2, Skup M.3, Wang S.3, Yang M.4, Yang H.4, Qi C.4, Bao Y.3, Chao J.3
1University of Calgary, AB, Canada, 2AbbVie Canada, St-Laurent, QC, Canada, 3AbbVie Inc., North 
Chicago, IL, 4Analysis Group, Inc., Boston, MA, USA
objeCtives: To evaluate the cost-effectiveness of adalimumab plus standard of 
care (ADA+SOC) vs. SOC alone in moderate-to-severe ulcerative colitis (UC) patients 
with an inadequate response to SOC and to assess the total cost differences compar-
ing ADA+SOC to infliximab (IFX)+SOC and to golimumab (GOL)+SOC. Methods: 
A Markov model was developed to simulate the progression of patients receiv-
ing ADA+SOC or SOC over a 5-year time horizon from the Canadian publicly-
funded health system’s perspective, considering direct costs only in the base case. 
Transitional probabilities of pre-surgery and surgery-related states for ADA+SOC 
and SOC were derived from ADA trials and from literature. Health utility and cost 
inputs (medications, medical services, surgery, and surgery-related mortality) came 
mainly from literature. Additionally, a cost-minimization analysis (CMA) compared 
the total 5-year costs of biologics (ADA, IFX and GOL) assuming IFX and GOL having 
the same efficacy as ADA. Results were expressed in costs per quality-adjusted-life-
years (QALY) gained for ADA+SOC vs. SOC alone and in total cost differences for 
ADA+SOC vs. IFX+SOC and vs. GOL+SOC. Deterministic and probabilistic sensitivity 
analyses (DSA, PSA) were performed. Results: In the base case, the incremen-
tal costs per QALY gained for ADA+SOC vs. SOC were C$96,812 (in 2013 Canadian 
dollars [C$]). Results from DSA ranged from C$62,362 to C$109,461. PSA revealed 
that ADA+SOC was cost-effective in 58% and 81% of cases at C$100,000/QALY and 
C$120,000/QALY thresholds, respectively. The CMA predicted total cost savings of 
C$23,823 and C$4,279 comparing ADA+SOC to IFX+SOC and to GOL+SOC over 5 
years. DSA and PSA results showed that ADA+SOC led to cost savings in all scenarios 
comparing to IFX+SOC and in all but one DSA-based and all PSA-based scenarios 
comparing to GOL+SOC. ConClusions: The ADA+SOC strategy appeared to pro-
vide reasonable cost-effectiveness value compared with SOC alone and significant 
cost-saving benefits compared to IFX+SOC and GOL+SOC.
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objeCtives: The seroprevalence of hepatitis C virus (HCV) is 16-41% in United 
States (US) prisons, yet no standard protocols exist for HCV screening. The objective 
of our study was to evaluate the cost-effectiveness HCV screening in prisons and 
HCV prevention in society by interventions in prisons Methods: We developed 
an agent-based simulation model that simulated the transmission and progres-
sion of HCV disease in US population in prisons and society. Injection drug use 
was the main route of HCV transmission. Chronic stages of HCV were modeled 
as Markov states. We used US Department of Justice data to simulate movement 
of people between prisons and society. We evaluated two screening scenarios: no 
screening, and 1-time screening of all existing inmates followed by screening (and 
treatment) of any incoming inmate for 5 years (5YR screening). We projected the 
